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Abstract
Background: Invasive growth of epithelial cancers is a complex multi-step process which involves
dissolution of the basement membrane. Type IV collagen is a major component in most basement
membranes. Type VII collagen is related to anchoring fibrils and is found primarily in the basement
membrane zone of stratified epithelia. Immunohistochemical studies have previously reported
changes in steady-state levels of different α(IV) chains in several epithelial cancer types. In the
present study we aimed to quantitatively determine the mRNA levels of type IV collagen (α1/α4/α6)
and type VII collagen (α1) during colorectal cancer carcinogenesis.
Methods: Using quantitative RT-PCR, we have determined the mRNA levels for α1(IV), α4(IV),
α6(IV), and α1(VII) in colorectal cancer tissue (n = 33), adenomas (n = 29) and in normal tissue from
the same individuals. In addition, corresponding tissue was examined from healthy volunteers (n =
20). mRNA levels were normalized to β-actin. Immunohistochemical analysis of the distributions of
type IV and type VII collagens were performed on normal and affected tissues from colorectal
cancer patients.
Results: The α1(IV) and α1(VII) mRNA levels were statistically significantly higher in colorectal
cancer tissue (p < 0.001) as compared to corresponding tissue from healthy controls. This is an
early event as tissue from adenomas also displayed a higher level. There were small changes in the
levels of α4(IV). The level of α6(IV) was 5-fold lower in colorectal cancer tissue as compared to
healthy individuals (p < 0.01). The localisation of type IV and type VII collagen was visualized by
immunohistochemical staining.
Conclusion: Our results suggest that the down-regulation of α6(IV) mRNA coincides with the
acquisition of invasive growth properties, whereas α1(IV) and α1(VII) mRNAs were up-regulated
already in dysplastic tissue. There are no differences in collagen expression between tissues from
healthy individuals and normal tissues from affected individuals.
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Background
The basement membrane (BM) acts as a barrier separating
the epithelium from the underlying stroma. BMs are com-
posed of a number of collagens and non-collageneous
proteins. Type IV collagen is a major component and is
present ubiquitously in all BMs [1,2]. Type IV collagen is
composed of six genetically distinct chains (α1(IV) to
α6(IV)) assembled in triple helical domains. Three molec-
ular forms of type IV collagen, composed of α1(IV)2/
α2(IV), α3(IV)/α4(IV)/α5(IV) and α5(IV)2/α6(IV), have
been characterized. The α1(IV) and α2(IV) chains are
widely distributed and found in all BMs of the whole
body whereas the α3(IV) – α6(IV) chains are distributed
in the BMs in a tissue-specific manner [3-6]. All six type IV
collagen  α-chains have been identified in the human
colon by immunofluorescence staining using chain-spe-
cific monoclonal antibodies [7]. Invasive growth is a hall-
mark of malignancy in cancers and several studies suggest
that the loss of tissue specific α(IV) chains in the epithelial
BM may be related to biologically significant events in the
invasive stage of cancer in different tissues [8-17].
Type VII collagen is related to BM anchoring fibrils and is
composed of three identical α chains in a triple helical
domain [18]. It is in addition to type IV collagen an
important component of collagen under stratified squa-
mous epithelium. A few studies have demonstrated the
presence of type VII collagen in normal colon as a linear
staining of the subepithelial BM [19,20] or in dysplastic
epithelium [17]. It has been suggested that type VII colla-
gen is involved in the process of early invasion [17].
In the previous studies, the distributions of type IV and
type VII collagen in normal and colorectal cancer tissue
have mainly been studied by use of immunohistochemi-
cal methods – a technique that allows a semi-quantitative
measure of the protein steady state level.
In the present study we have for the first time investigated
the mRNA levels of type IV collagen (α1(IV),  α4(IV),
α6(IV)), and type VII collagen in affected and normal tissue
from individuals with colorectal adenomas and carcino-
mas as well as in normal tissue from healthy individuals.
Our aim was to investigate which changes in the mRNA
levels of the BM collagens coincide with the acquisition of
invasive growth properties.
Methods
Subject population
The KAM cohort (Kolorektal cancer, Arv og Miljø) is based
primarily on the screening group of the Norwegian Color-
ectal Cancer Prevention study (the NORCCAP study) in
the county of Telemark, Norway [21]. Additionally, a
series of colorectal cancer cases was recruited to the KAM
cohort from routine clinical work at Telemark Hospital in
Skien and Ullevål University Hospital in Oslo. In the
NORCCAP study a total of 20,780 men and women, age
distribution 50–64 years, drawn randomly from the pop-
ulation registries in Oslo (urban) and the county of Tele-
mark (mixed urban and rural) were invited to have a
flexible sigmoidoscopy (FS) screening examination with
or without (1:1) an additional faecal occult blood test
(FOBT). 777 (4%) individuals were excluded as previ-
oualy described [21]. The KAM biobank currently consists
of 234 colorectal cancer cases, 1044 cases with adenomas
(229 high-risk, 762 low-risk and 53 hyperplastic polyps)
and 400 controls. Controls were defined as individuals
with normal findings at FS. In the present study we ana-
lyzed cases with carcinoma (n = 33) and adenoma (n =
29). For individuals with adenoma a sample of control tis-
sue was collected 30 cm from the anus. For patients with
carcinoma two samples of control tissue were taken from
the surgical specimen, one sample in close proximity
(normal adjacent), and one sample as far away from the
tumour as possible (normal distant). Control samples
from healthy controls were taken from individuals (n =
20) where no adenomas or carcinomas could be identi-
fied with FS. The histology was examined independently
by two histopathologists. The specimens were put into
liquid nitrogen as fast as possible after surgical removal.
The colorectal cancer patients were classified according to
Dukes system (A: Invasion but not through the bowel
wall. B: Invasion but through the bowel wall but not
involving lymph nodes. C: Involvement of lymph nodes.
D: Widespread metastases.)
The KAM study is approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate, and informed consent has been obtained.
The ID number for the NORCCAP study at Clinicaltri-
als.gov is NCT00119912 [22].
RNA purification and cDNA synthesis
Total RNA was purified from tissue as recommended by
the manufacturers using E.Z.N.A. Total RNA Kit II (VWR,
Copenhagen, Denmark). The tissue had been stored in
liquid N2  before RNA purification. RNA purification
included a DNAse treatment. The cDNA synthesis was per-
formed on approximately 200 ng RNA per 20 μl using
High-Capacity cDNA Archive Kit (Applied Biosystems).
Quantitative RT-PCR
Quantitative RT-PCR was performed using SYBR® Green.
All assays were performed using the ABI 7300 Sequence
Detection System (Applied Biosystems).
Primers were obtained from TAG Copenhagen.α1(IV) F,
5'-CAG CCA GAC CAT TCA GAT CC-3';α1(IV) R, 5'-GGC
GTA GGC TTC TTG AAC AT-3' [12]. α4(IV) F, 5'-AGA GAT
TGC TCT GTT TGC CAC-3'; α4(IV) R, 5'-CGG TCC CCTBMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
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CTC ATT CCT T-3' (Primerbank). α6(IV) F, 5'-CTC CTT
GCC CTC ACT CAT AGC-3'; α6(IV) R, 5'-GTC TCC CTT
AGG CCC TTT AGG-3' (Primerbank) α1(VII) F, 5'-CGG
AAC TGA CCA TCC AGA AT-3'; – 3' α1(VII) R, 5'-AAT
AGG GTG CTC ACG GTC AC-3' [23]. β-actin F, 5'-CTG
GCA CCC AGC ACA ATG-3'; β-actin R, 5'-AGC GAG GCC
AGG ATG GA-3' (Primer Express 3.0). The PCR reactions
were performed using 900/50/900/300/900 nM F primer
and 900/300/300/300/900 nM R primers for α1(IV),
α4(IV), α6(IV), α1(VII) and β-actin respectively. Quanti-
tative Power SYBR® Green PCR master mix (Applied Bio-
systems) was used accordingly to the instructions from the
manufacturer. To ensure that the PCR efficiency was equal
for both the target gene and the reference gene, we made
an efficiency plot with a serial dilution of cDNA. The val-
idation showed that the assays are quantitative over a
range of 256/128/16/64/256-fold dilution for α1(IV),
α4(IV), α6(IV), α1(VII) provided that a threshold of 0.2 is
used for all primer sets. The threshold is a fixed fluores-
cence signal level above the baseline, and the Ct value of a
sample is determined as the fractional cycle number
where the sample's fluorescence signal exceeds the thresh-
old. The collagens and β-actin were quantified in separate
wells in duplicates. The standard deviation on repeated
measurements of the same sample (the control) in sepa-
rate experiments was 4%, 19%, 30% and 12% for α1(IV),
α4(IV), α6(IV) and α1(VII) respectively, indicating the
day-to-day variability of the assay. Negative controls
(where the RNA is not converted into cDNA) and positive
controls were included in all sets.
Statistical analysis
MiniTab Statistical Software, Release 13.1 Xtra (Minitab
Inc.), and GraphPad Prism 4 were used for the statistical
calculations. The data were not adjusted for gender since
the incidence ratio of colorectal cancer between the gen-
ders is 1:1 in Norway [24].
Immunohistochemistry
The frozen, unfixed tissue sections were mounted on a
precooled cryostat table by use of Tissue-Tek (Sakura Fine-
tek). 7 μm thick sections were cut on a Leitz cryostat at -
20°C and collected on glass slides. The sections were
examined by immunofluorescence microscopy for the
localization of type IV and type VII collagens using poly-
clonal rabbit anti type IV collagen (Abcam 6586) and
monoclonal mouse anti-type VII collagen (Abcam 6312),
respectively. All primary antibodies were diluted 1:100.
Alexa Fluor goat anti-mouse IgG conjugate or Alexa Fluor
goat anti-rabbit IgG conjugate (1:400 or 1:800) were used
as secondary antibodies. Controls without primary anti-
body were run in parallel. The sections were finally
mounted in antifade mounting medium, with or without
DAPI (Vector Laboratories Inc.), and examined in a Leica
DM 4000B microscope equipped with a Leica DC 300 FX
camera.
Results
The distribution of type IV and type VII collagen is shown
in Fig 1. In normal tissue from controls and colorectal
cancer patients type IV collagen was widely distributed in
the extracellular matrix along the BM below the epithelial
cells, in the perivascular stroma, and in the muscularis
mucosa. In colorectal cancer tissue type IV collagen was
detected in the same structures surrounding the distorted
epithelial layer. In normal tissue type VII collagen could
be detected at the BM of the surface epithelial cells, but
could not be detected along the crypts or in other parts of
the extracellular matrix. In the colorectal cancer tissue type
VII collagen could be detected as a band below the epithe-
lial cells in the distorted epithelium. None of the controls
showed any staining.
The mRNA levels for α1(IV), α4(IV), α6(IV), and α1(VII)
collagens  were measured in colon tissue samples from
healthy control individuals (n = 20) and in healthy and
Location of type IV collagen and type VII collagen in normal  and colorectal cancer tissue from the same patient Figure 1
Location of type IV collagen and type VII collagen in 
normal and colorectal cancer tissue from the same 
patient. Frozen tissue sections were incubated on the glass 
slide with polyclonal rabbit anti-type IV collagen and mono-
clonal mouse anti-type VII collagen. Negative controls with-
out primary antibody were run in parallel (not shown). The 
bar represents 50 μm.BMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
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affected tissue from individuals with adenomas (n = 29)
and with colorectal cancer (n = 33) by real-time RT-PCR.
Two histologically normal samples were analyzed from
individuals with colorectal cancer, one "normal distant"
taken as far away from the cancer tissue as allowed by the
surgically removed tissue, and one "normal adjacent"
taken immediately adjacent to the colorectal cancer tissue.
We chose to normalize the mRNA levels of the collagens to
the mRNA level of β-actin. The adenomas were character-
ized as mild dysplasia (n = 1), moderate dysplasia (n = 22)
or non-determined (n = 6). The characteristics of the cases
and healthy persons used in this study are shown in Table
1.
mRNA levels for α1(IV), α4(IV), α6(IV) and α1(VII) col-
lagens  normalized to β-actin  are shown in Fig. 2. The
α1(IV) mRNA level was increased both in adenomas and
colorectal cancer tissue. The α1(IV) mRNA level of color-
ectal cancer tissue was 6-fold higher than the correspond-
ing tissue from healthy individuals (p < 0.001) (Table 2
and Fig. 2). When comparing affected tissue with normal
tissue from the same individual, we found a statistically
significant difference between individuals with adenomas
(p < 0.001) and individuals with colorectal cancer when
compared to both the normal distant and normal adja-
cent tissues (p < 0.001).
mRNA level for α4(IV) displayed little change during car-
cinogenesis (Fig. 2). We found no statistically significant
differences when comparing the level of α4(IV) mRNA in
the various groups with corresponding tissue from
healthy individuals. The mRNA level for α4(IV)  was
slightly but statistically significantly lower in adenomas
when normal and affected tissue from the same individual
was compared (p < 0.001). A similar decrease was
observed when normal adjacent and colorectal cancer tis-
sue were compared (p < 0.01). However, no statistically
significant difference was seen when comparing the nor-
mal distant samples with colorectal cancer tissue.
mRNA level for α6(IV) was decreased in colorectal cancer
tissue (Fig. 2.). Compared with the level of α6(IV) mRNA
in tissue from healthy individuals there was a statistically
significant 5-fold decrease in colorectal cancer tissue (p <
0.05). When comparing normal and affected tissue from
the same individual statistically significant differences
were seen in colorectal cancer patients both when com-
pared to normal distant and normal adjacent tissue (p <
0.001). However, no differences in mRNA levels were
detected when comparing normal and affected tissue from
individuals with adenomas.
mRNA level for Type VII collagen was increased in both
adenomas and colorectal cancer tissue (Fig. 2.). The level
of mRNA for α1(VII) collagen was increased 3.5-fold in
colorectal cancer tissue compared to normal tissue in
healthy individuals (p < 0.01). mRNA for α1(VII) collagen
was statistically significantly increased in individuals with
adenomas (p < 0.01) and carcinomas (p < 0.001) when
comparing affected and normal tissue from the same indi-
vidual.
The colorectal cancer patients were staged as Dukes grade
A (n = 6), grade B (n = 25) and grade C (n = 16). No Dukes
grade D patients were found in this set of samples. No ten-
dency and no statistically significant differences (one-way
ANOVA and Tukey's post test for paired comparison) were
seen when comparing the α1(IV), α4(IV), α6(IV), and
α1(VII) mRNA levels in the different Dukes groups.
Discussion
In the present study we have determined the mRNA levels
of type IV collagen (chains α1(IV), α4(IV), α6(IV)) and type
VII collagen (chain α1(VII)) during colorectal cancer car-
cinogenesis.
Former studies on colorectal normal and neoplastic tis-
sues have been performed on a relatively small number of
patients often not including controls from healthy indi-
viduals. Furthermore, former studies have primarily used
immunohistochemistry, a technique that can demon-
strate the presence of the proteins but only in a semi-
quantitative manner. In the present study we have
included control samples from healthy individuals in
addition to normal tissue from individuals with adeno-
mas and carcinomas. In addition, we have used quantita-
tive real time RT-PCR to indicate the levels of mRNAs
coding for collagen chains. To the best of our knowledge
this is the first quantitative assessment of changes in col-
lagen mRNA levels during carcinogenesis.
Our results show, that the normal and neoplastic colon
mucosa express α1/α4/α6(IV) collagens. This confirms ear-
lier results obtained by immunohistochemistry staining
using chain-specific monoclonal antibodies [7]. When
Table 1: Characteristics of cases and healthy persons used in this 
study
Healthy Cases
Adenomas Carcinomas
(n = 20) (n = 29) (n = 33)
Men 8 21 20
Women 12 8 13
Mean age +SD1 56.0 ± 4.6 56.9 ± 3.8 68.8 ± 11.4
1The patients with carcinoma are significantly older than the two 
other groups at 95% confidence level (Kruskal-Wallis test).BMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
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Figure 2 (see legend on next page)
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examining the level of mRNA for α1(IV) we found an ele-
vated level already in adenomas that is maintained in the
colorectal cancer tissue compared to both corresponding
tissue from healthy individuals and histologically normal
tissue from the colorectal cancer patients. The change in
α1(IV) mRNA levels detected in this study therefore do
not coincide with acquisition of invasive growth proper-
ties. Since α1(IV) is widely distributed in the tissue, and
not only in the subepithelial BM, its shown up-regulation
in the neoplastic tissue might be connected to an
increased amount of α1(IV)  in stromal BMs as well.
Immunohistological studies have previously suggested
that α1(IV) is down-regulated in colorectal cancer in rela-
tion to tumour differentation [7]. However, when com-
paring tumours with different Dukes stages we did not
show significant differences.
We found a diminished mRNA level for α4(IV) in adeno-
mas and cancer tissue as compared to normal control tis-
sue in the same patient. This result is in agreement with a
previous study where α4(IV) was undetectable by immu-
nohistochemistry in colon tumour biopsies, but was
detectable in normal tissue from the same individual [7].
It has also been described that α4(IV) is partly lost in
bronchioalveolar carcinoma of the lung but present in
histologically normal adjacent tissue [15]. α4(IV) colla-
gen is localized exclusively in the BM below the colonic
epithelial surface and might thus be of interest regarding
invasiveness of malignant neoplasms. However, we found
that the change of α4(IV) mRNA level is rather small and
do not coincide with acquisition of invasive growth prop-
erties.
By quantitative RT-PCR we found that the mRNA level for
α6(IV) was significantly down-regulated in colorectal can-
cer tissue compared to both healthy individuals and nor-
mal control tissue in the patients with carcinoma. There
was no significant reduction in adenoma tissue. The loss
of α6(IV) is in agreement with suggestions from earlier
immunohistochemical studies in colorectal carcinoma
[7,11]. In addition, loss of or the diminished presence of
α5–6(IV) collagens have been demonstrated by immuno-
histochemistry in prostatic carcinoma [10], in basal cell
carcinoma [25], in lung adenocarcinoma [15], and in gas-
tric intramucosal carcinoma [8]. In contrast to α1(IV)
which is widely distributed, α6(IV) is localized exclusively
to the subepithelial BM along the luminal surface and the
crypts in the colon [7] and is therefore of special interest
regarding the question of invasive growth. In this study we
find that the down-regulation of the level of mRNA for
α6(IV) is a late event in carcinogenesis that coincides with
acquisition of invasive growth properties. We therefore
suggest that down-regulation of α6(IV)  might be an
important factor for acquisition of invasive growth prop-
erties of the tumour.
Our immunohistochemical studies show that type VII col-
lagen is present in normal and neoplastic colonic tissue.
Our quantitative real-time RT-PCR results show for the
first time that there is a significant up-regulation of the
level of mRNA for α1(VII) collagen in colorectal cancer tis-
sue compared to both corresponding tissue from healthy
individuals and normal tissue from patients with carci-
noma. We found that individuals with adenomas have a
significant increase in the level of α1(VII) mRNA in the
adenoma tissue compared to normal tissue from the same
individual. There are no significant differences between
tissue from healthy individuals and normal tissue taken
from individuals with adenomas or carcinomas. The up-
regulation of α1(VII) mRNA is thus already seen in indi-
viduals with adenomas and maintained in carcinomas.
The pattern of mRNA levels is very similar to the pattern
seen for α1(IV). However, as seen by histochemistry type
VII collagen is localized solely beneath the surface epithe-
lial cells and therefore – in contrast to α1(IV) specifically
reflects alterations along the epithelial BM. Interestingly,
the same localization is described for α3/α4(IV) by the
use of chain specific antibodies [7]. It might be speculated
whether up-regulation of α1(VII) in concert with down-
regulation of α4(IV) results in alterations of importance
for invasiveness.
Type VII collagen is also known as the epidermolysis bul-
losa acquisita antigen since patients with this disease have
IgG auto-antibodies against type VII collagen. A few other
studies have shown the presence of type VII collagen in
normal colon [19,20]. Visser et al., (1993) demonstrated
type VII collagen immunoreactivity in the BM zone in ade-
nomas and adenocarcinomas but not in normal colon
epithelium from 4 control patients and suggested that
The mRNA levels of mRNA for α1(IV), α4(IV), α6(IV) and α1(VII) collagens determined by real-time RT-PCR from healthy indi- viduals (Normal), normal tissue from individuals with adenoma (Adenoma control), tissue from adenomas (Adenomas), normal  tissue from colorectal cancer patients taken as far away from the carcinoma as possible from the surgically removed tissue  (Normal distant), normal tissue from colorectal cancer patients taken near to the carcinoma (Normal adjacent) or colorectal  cancer tissue (CRC) Figure 2 (see previous page)
The mRNA levels of mRNA for α1(IV), α4(IV), α6(IV) and α1(VII) collagens determined by real-time RT-PCR 
from healthy individuals (Normal), normal tissue from individuals with adenoma (Adenoma control), tissue 
from adenomas (Adenomas), normal tissue from colorectal cancer patients taken as far away from the carci-
noma as possible from the surgically removed tissue (Normal distant), normal tissue from colorectal cancer 
patients taken near to the carcinoma (Normal adjacent) or colorectal cancer tissue (CRC). Each dot represents 
one individual. All mRNA levels were normalized to the level of β-actin mRNA.BMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
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Table 2: α1(IV), α4(IV), α6(IV) and α1(VII) mRNA levels in normal and neoplastic colonic tissues.
mRNA level in normal tissue*
Mean (SD)
pa mRNA level in neoplastic tissue
Mean (SD)
pa pb
α1(IV)
Healthy individual 8.3 × 10-3 (6.5 × 10-3)
Patients with adenoma 6.3 × 10-3 (2.6 × 10-3) NS 20.6 × 10-3 (10.4 × 10-3)N S <  0 . 0 0 1
Patients with carcinoma 15.0 × 10-3 (14.6 × 10-3)** NS 53.6 × 10-3 (42.0 × 10-3) < 0.001 < 0.001
Patients with carcinoma 20.2 × 10-3 (17.8 × 10-3)*** NS 53.6 × 10-3 (42.0 × 10-3)<  0 . 0 0 1
α4(IV)
Healthy individual 8.8 × 10-5 (3.6 × 10-5)
Patients with adenoma 8.6 × 10-5 (3.7 × 10-5)N S 4 . 4  ×  1 0 -5 (3.5 × 10-5)N S <  0 . 0 0 1
Patients with carcinoma 17.5 × 10-5(18.7 × 10-5)** NS 11.4 × 10-5 (15.9 × 10-5)N S N S
Patients with carcinoma 20.1 × 10-5 (16.9 × 10-5)*** NS 11.4 × 10-5 (15.9 × 10-5)<  0 . 0 1
α6(IV)
Healthy individual 8.2 × 10-5 (4.6 × 10-5)
Patients with adenoma 9.4 × 10-5 (5.6 × 10-5)N S 9 . 3  ×  1 0 -5 (6.3 × 10-5)N S N S
Patients with carcinoma 7.1 × 10-5 (9.5 × 10-5)** NS 1.5 × 10-5 (2.8 × 10-5) < 0.05 < 0.001
Patients with carcinoma 7.4 × 10-5 (9.8 × 10-5)*** NS 1.5 × 10-5 (2.8 × 10-5)<  0 . 0 0 1
α1(VII)
Healthy individual 5.1 × 10-6 (1.8 × 10-6)
Patients with adenoma 5.2 × 10-6 (3.8 × 10-6)N S 9 . 6  ×  1 0 -6 (6.0 × 10-6)N S <  0 . 0 1
Patients with carcinoma 7.3 × 10-6 (7.6 × 10-6)** NS 17.8 × 10-6 (1.9 × 10-6) < 0.01 < 0.001
Patients with carcinoma 7.3 × 10-6 (8.0 × 10-6)*** NS 17.8 × 10-6 (1.9 × 10-6)<  0 . 0 0 1
The mRNA levels were normalized to β-actin mRNA levels.
*Normal tissue: histologically normal colonic biopsies taken from healthy individuals or individuals with adenomas or carcinoma: ** = normal tissue 
taken from surgical specimens as distant from the carcinoma as possible; *** = normal tissue taken in close proximity to the carcinoma.
NS = not significant (P > 0.05)
a) p value for the comparison of the mRNA levels in normal tissue from healthy individuals with either normal or neoplastic tissue from patients 
using a one-way ANOVA and Tukey's Multiple Comparison Test.
b) p value for the comparison of the mRNA levels in normal and neoplastic tissue from the same patient using paired T-test.BMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
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type VII collagen is involved in the process of early inva-
sion [17]. We find that the up-regulation of α1(VII)
mRNA occurs as an early event prior to the acquisition of
invasive growth. We therefore suggest that up-regulation
of α1(VII) mRNA might be a necessary but not sufficient
event in the process of carcinogenesis.
The fact that there are no significant differences between
tissue from healthy individuals and the normal tissue
taken from the individual with adenomas or carcinomas
suggests that it is not a primary defect in the mRNA levels
of the single type IV collagen chains or type VII collagen
that leads to development of cancer.
Conclusion
In conclusion, we found that the mRNA levels of α6(IV)
was down-regulated as a late event that coincides with the
acquisition of invasive growth properties. α1(IV)  and
α1(VII) mRNAs were increased already in adenoma tissue
and maintained at a high level in colorectal cancer tissue.
A change that may be necessary but not sufficient for
acquisition of invasive growth properties. Future studies
are required to clarify whether changes in collagen com-
position are a cause or a consequence of malignant pro-
gression.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HS conceived the idea of the study and designed the col-
lagen primers. HS and DA performed the immunohisto-
chemistry. EHK designed and administered the KAM
study and collected the samples. IMBL evaluated the tissue
sections. KMT contributed with scientific advice to the
KAM study. LV and DA carried out and evaluated the RT-
PCR. LV performed the statistical evaluation. All authors
helped interpret the results, writing the manuscript and
approved the final version.
Acknowledgements
The KAM study was supported by the Norwegian Cancer Society, the Nor-
wegian Colorectal Cancer Prevention (NORCCAP) study (Grants from the 
Norwegian Cancer Society and the Department of Health and Social 
Affairs), and Eastern Norway Regional Health Authority.
Associate professor Gert Hansen, Department of Cellular and Molecular 
Medicine, University of Copenhagen is thanked for assistance with the 
immunofluorescense microscopic studies. Christel Halberg is thanked for 
excellent technical assistance.
References
1. Kalluri R: Basement membranes: structure, assembly and
role in tumour angiogenesis.  Nat Rev Cancer 2003, 3:422-433.
2. Timpl R: Structure and biological activity of basement mem-
brane proteins.  Eur J Biochem 1989, 180:487-502.
3. Mariyama M, Leinonen A, Mochizuki T, Tryggvason K, Reeders ST:
Complete primary structure of the human alpha 3(IV) colla-
gen chain. Coexpression of the alpha 3(IV) and alpha 4(IV)
collagen chains in human tissues.  J Biol Chem 1994,
269:23013-23017.
4. Ninomiya Y, Kagawa M, Iyama K, Naito I, Kishiro Y, Seyer JM, Sugim-
oto M, Oohashi T, Sado Y: Differential expression of two base-
ment membrane collagen genes, COL4A6 and COL4A5,
demonstrated by immunofluorescence staining using pep-
tide-specific monoclonal antibodies.  J Cell Biol 1995,
130:1219-1229.
5. Sado Y, Kagawa M, Naito I, Ueki Y, Seki T, Momota R, Oohashi T,
Ninomiya Y: Organization and expression of basement mem-
brane collagen IV genes and their roles in human disorders.
J Biochem 1998, 123:767-776.
6. Simoneau A, Herring-Gillam FE, Vachon PH, Perreault N, Basora N,
Bouatrouss Y, Pageot LP, Zhou J, Beaulieu JF: Identification, distri-
bution, and tissular origin of the alpha5(IV) and alpha6(IV)
collagen chains in the developing human intestine.  Dev Dyn
1998, 212:437-447.
7. Oka Y, Naito I, Manabe K, Sado Y, Matsushima H, Ninomiya Y,
Mizuno M, Tsuji T: Distribution of collagen type IV alpha1-6
chains in human normal colorectum and colorectal cancer
demonstrated by immunofluorescence staining using chain-
specific epitope-defined monoclonal antibodies.  J Gastroenterol
Hepatol 2002, 17:980-986.
8. Baba Y, Iyama K, Ikeda K, Ishikawa S, Hayashi N, Miyanari N, Honda
Y, Sado Y, Ninomiya Y, Baba H: Differential expression of base-
ment membrane type IV collagen alpha chains in gastric
intramucosal neoplastic lesions.  J Gastroenterol 2007,
42:874-880.
9. Baba Y, Iyama K, Ikeda K, Ishikawa S, Hayashi N, Miyanari N, Sado Y,
Ninomiya Y, Baba H: The expression of type IV collagen alpha6
chain is related to the prognosis in patients with esophageal
squamous cell carcinoma.  Ann Surg Oncol 2008, 15:555-565.
10. Dehan P, Waltregny D, Beschin A, Noel A, Castronovo V, Tryggvason
K, De Leval J, Foidart JM: Loss of type IV collagen alpha 5 and
alpha 6 chains in human invasive prostate carcinomas.  Am J
Pathol 1997, 151:1097-1104.
11. Hiki Y, Iyama K, Tsuruta J, Egami H, Kamio T, Suko S, Naito I, Sado Y,
Ninomiya Y, Ogawa M: Differential distribution of basement
membrane type IV collagen alpha1(IV), alpha2(IV),
alpha5(IV) and alpha6(IV) chains in colorectal epithelial
tumors.  Pathol Int 2002, 52:224-233.
12. Ikeda K, Iyama K, Ishikawa N, Egami H, Nakao M, Sado Y, Ninomiya
Y, Baba H: Loss of expression of type IV collagen alpha5 and
alpha6 chains in colorectal cancer associated with the hyper-
methylation of their promoter region.  Am J Pathol 2006,
168:856-865.
13. Martinella-Catusse C, Polette M, Noel A, Gilles C, Dehan P, Munaut
C, Colige A, Volders L, Monboisse JC, Foidart JM, Birembaut P:
Down-Regulation of MT1-MMP expression by the alpha3
chain of type IV collagen inhibits bronchial tumor cell line
invasion.  Lab Invest 2001, 81:167-175.
14. Misumi S, Iyama K, Honda Y, Kitano T, Sado Y, Ninomiya Y, Shinohara
M: Differential expression of basement membrane type-IV
collagen alpha1, alpha2, alpha5 and alpha6 chains among the
histological subtypes of adenoid cystic carcinoma.  Virchows
Arch 2004, 445:54-62.
15. Nakano KY, Iyama KI, Mori T, Y o s h i o k a  M ,  H i r a o k a  T ,  S a d o  Y ,
Ninomiya Y: Loss of alveolar basement membrane type IV col-
lagen alpha3, alpha4, and alpha5 chains in bronchioloalveolar
carcinoma of the lung.  J Pathol 2001, 194:420-427.
16. Tanjore H, Kalluri R: The role of type IV collagen and basement
membranes in cancer progression and metastasis.  Am J Pathol
2006, 168:715-717.
17. Visser R, Arends JW, Leigh IM, Bosman FT: Patterns and compo-
sition of basement membranes in colon adenomas and ade-
nocarcinomas.  J Pathol 1993, 170:285-290.
18. Christiano AM, Greenspan DS, Lee S, Uitto J: Cloning of human
type VII collagen. Complete primary sequence of the alpha
1(VII) chain and identification of intragenic polymorphisms.
J Biol Chem 1994, 269:20256-20262.
19. Chen M, O'Toole EA, Sanghavi J, Mahmud N, Kelleher D, Weir D,
Fairley JA, Woodley DT: The epidermolysis bullosa acquisita
antigen (type VII collagen) is present in human colon and
patients with crohn's disease have autoantibodies to type VII
collagen.  J Invest Dermatol 2002, 118:1059-1064.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:136 http://www.biomedcentral.com/1471-2407/9/136
Page 9 of 9
(page number not for citation purposes)
20. Lohi J, Leivo I, Tani T, Kiviluoto T, Kivilaakso E, Burgeson RE, Virtanen
I:  Laminins, tenascin and type VII collagen in colorectal
mucosa.  Histochem J 1996, 28:431-440.
21. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The
Norwegian Colorectal Cancer Prevention (NORCCAP)
screening study: baseline findings and implementations for
clinical work-up in age groups 50–64 years.  Scand J Gastroenterol
2003, 38:635-642.
22. Clinical Trials  2007 [http://clinicaltrials gov].
23. Wang TW, Sun JS, Huang YC, Wu HC, Chen LT, Lin FH: Skin base-
ment membrane and extracellular matrix proteins charac-
terization and quantification by real time RT-PCR.
Biomaterials 2006, 27:5059-5068.
24. Norway TCR: Cancer in Norway 2004. Oslo, Infoprint 2006 [http://
www.kreftregisteret.no/en/].
25. Tanaka K, Iyama K, Kitaoka M, Ninomiya Y, Oohashi T, Sado Y, Ono
T: Differential expression of alpha 1(IV), alpha 2(IV), alpha
5(IV) and alpha 6(IV) collagen chains in the basement mem-
brane of basal cell carcinoma.  Histochem J 1997, 29:563-570.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/136/pre
pub